Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Debabrata Mukhopadhyay

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-1858-5054; OpenAlex author ID A5060391092; NIH RePORTER profile ID 6521858. Sources: OpenAlex.

Their work

Papers
35 (first author 2, last author 13)
Trials
0
Grants
2
Labs led
2
Collaborators
82
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: 1 paper · 2014: 2 papers · 2015: 1 paper · 2016: 1 paper · 2017: 3 papers · 2018: 1 grant · 2019: 6 papers · 2020: 1 paper · 2021: 4 papers, 1 grant · 2022: 2 papers · 2023: none · 2024: 3 papers · 2025: 3 papers · 2026: 5 papers

Papers 35

  1. Tumor Treating Fields (TTFields) potentiate cisplatin efficacy and remodel the transcriptional landscape in preclinical models of pancreatic ductal adenocarcin… Co-author DOI 10.1016/j.canlet.2026.218651↗
  2. AI-driven discovery and validation of a GIPC1 PDZ domain inhibitor for pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.celrep.2026.117777↗
  3. Amphiphilic Glycopolymer Nanoparticles for pH-Responsive Paclitaxel Delivery and Enhanced Efficacy in Pancreatic Ductal Adenocarcinoma Therapy. Last author DOI 10.1021/acsabm.5c02077↗
  4. Targeting drug efflux in pancreatic cancer: what the PANTAX trial teaches us about resisting resistance. First author DOI 10.21037/apc-26-0044↗
  5. Combining Tumor Treating Fields with Immunotherapy in Pancreatic Ductal Adenocarcinoma: Mechanisms, Preclinical Evidence, and Emerging Therapeutic Synergy. Co-author DOI 10.3390/cells15090845↗
  6. Jorunnamycin A induces apoptosis in pancreatic ductal adenocarcinoma cells, spheroids, and patient-derived organoids by modulating KRAS-mediated survival pathw… Co-author DOI 10.1038/s41598-025-95766-5↗
  7. Tumor-Treating Fields Alter Nanomechanical Properties of Pancreatic Ductal Adenocarcinoma Cells Co-Cultured with Extracellular Matrix. Co-author DOI 10.3390/jfb16050160↗
  8. Lipid Nanoparticle-Mediated RNAi Against GIPC1 Overcomes Chemoresistance in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/pharmaceutics17101334↗
  9. Dual drug-loaded tumor-targeted polymeric nanoparticles for enhancing therapeutic response in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.mtbio.2024.101199↗
  10. Roflumilast inhibits tumor growth and migration in STK11/LKB1 deficient pancreatic cancer. Co-author DOI 10.1038/s41420-024-01890-y↗
  11. Surface Chemistry of Gold Nanoparticles Modulates Cytokines and Nanomechanical Properties in Pancreatic Cancer Cell Lines: A Correlative Study. Co-author DOI 10.26502/fjhs.170↗
  12. Aurora kinase a inhibitor MLN8237 suppresses pancreatic cancer growth. Co-author DOI 10.1016/j.pan.2022.03.019↗
  13. CDK7 inhibition augments response to multidrug chemotherapy in pancreatic cancer. Co-author DOI 10.1186/s13046-022-02443-w↗
  14. Nanomechanical Insight of Pancreatic Cancer Cell Membrane during Receptor Mediated Endocytosis of Targeted Gold Nanoparticles. First author DOI 10.1021/acsabm.0c01443↗
  15. Tyrosine Phosphoproteomics of Patient-Derived Xenografts Reveals Ephrin Type-B Receptor 4 Tyrosine Kinase as a Therapeutic Target in Pancreatic Cancer. Co-author DOI 10.3390/cancers13143404↗
  16. Muscle-Derived Cytokines Reduce Growth, Viability and Migratory Activity of Pancreatic Cancer Cells. Co-author DOI 10.3390/cancers13153820↗
  17. Role of PLEXIND1/TGFβ Signaling Axis in Pancreatic Ductal Adenocarcinoma Progression Correlates with the Mutational Status of KRAS. Last author DOI 10.3390/cancers13164048↗
  18. Targeted Dual Intervention-Oriented Drug-Encapsulated (DIODE) Nanoformulations for Improved Treatment of Pancreatic Cancer. Last author DOI 10.3390/cancers12051189↗
  19. Tumor selective uptake of drug-nanodiamond complexes improves therapeutic outcome in pancreatic cancer. Co-author DOI 10.1016/j.nano.2019.02.020↗
  20. Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic… Co-author DOI 10.1021/acs.bioconjchem.9b00632↗
  21. Development of multi-drug loaded PEGylated nanodiamonds to inhibit tumor growth and metastasis in genetically engineered mouse models of pancreatic cancer. Last author DOI 10.1039/c9nr05478b↗
  22. Phases of Metabolic and Soft Tissue Changes in Months Preceding a Diagnosis of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2019.01.039↗
  23. DNA-SWCNT Biosensors Allow Real-Time Monitoring of Therapeutic Responses in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/0008-5472.can-18-3337↗
  24. Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR-Mediated DNA Damage Response. Co-author DOI 10.1158/1078-0432.ccr-19-0799↗
  25. Mixed poly(vinyl pyrrolidone)-based drug-loaded nanomicelles shows enhanced efficacy against pancreatic cancer cell lines. Co-author DOI 10.1016/j.ejps.2017.03.021↗
  26. Immunosuppressive CD14+HLA-DR lo/neg monocytes are elevated in pancreatic cancer and "primed" by tumor-derived exosomes. Last author DOI 10.1080/2162402x.2016.1252013↗
  27. Preclinical efficacy of the novel competitive NAMPT inhibitor STF-118804 in pancreatic cancer. Co-author DOI 10.18632/oncotarget.18841↗
  28. Pathogenesis of pancreatic cancer exosome-induced lipolysis in adipose tissue. Last author DOI 10.1136/gutjnl-2014-308350↗
  29. Pancreatic Cancer-Derived Exosomes Cause Paraneoplastic β-cell Dysfunction. Last author DOI 10.1158/1078-0432.ccr-14-2022↗
  30. Inhibition of endoglin-GIPC interaction inhibits pancreatic cancer cell growth. Last author DOI 10.1158/1535-7163.mct-14-0291↗
  31. GAIP interacting protein C-terminus regulates autophagy and exosome biogenesis of pancreatic cancer through metabolic pathways. Last author DOI 10.1371/journal.pone.0114409↗
  32. New insights into pancreatic cancer-induced paraneoplastic diabetes. Co-author DOI 10.1038/nrgastro.2013.49↗
  33. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Co-author DOI 10.1038/nature11547↗
  34. Adrenomedullin is up-regulated in patients with pancreatic cancer and causes insulin resistance in β cells and mice. Co-author DOI 10.1053/j.gastro.2012.08.044↗
  35. Designing nanoconjugates to effectively target pancreatic cancer cells in vitro and in vivo. Co-author DOI 10.1371/journal.pone.0020347↗

Grants 2

  1. Targeting Pancreatic Cancer Using Peptide Chemistry: From Bench to Bedside R01CA150190↗
  2. Administrative Core P50CA102701↗

Closest collaborators

The 25 strongest of 82 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Santanu Bhattacharya · 10 shared papers, 2014–2026 · strength 2.11
  2. Hani M. Babiker · 6 shared papers, 2024–2026 · strength 1.88
  3. Krishnendu Pal · 11 shared papers, 2014–2026 · strength 1.59
  4. Hari Krishnareddy Rachamala · 5 shared papers, 2024–2026 · strength 1.37
  5. Tanmay Kulkarni · 4 shared papers, 2021–2026 · strength 1.06
  6. Vijay Sagar Madamsetty · 8 shared papers, 2019–2025 · strength 1.04
  7. Naga Malleswara Rao Nakka · 3 shared papers, 2024–2026 · strength 0.71
  8. Douaa Albelal · 2 shared papers, 2026 · strength 0.62
  9. Christian P. Pilarsky · 4 shared papers, 2021–2025 · strength 0.61
  10. Andrew Victor Biankin · 4 shared papers, 2021–2025 · strength 0.61
  11. David Kuang-Fu Chang · 4 shared papers, 2021–2025 · strength 0.58
  12. Suresh T. Chari · 7 shared papers, 1 shared grant, 2012–2019 · strength 0.51
  13. Nayef Hikmat Abdel-Razeq · 1 shared paper, 2026 · strength 0.50
  14. Bin Lan · 3 shared papers, 2022–2025 · strength 0.48
  15. Robert Grützmann · 3 shared papers, 2022–2025 · strength 0.48
  16. Dale F Mierke · 1 shared grant, 2021 · strength 0.44
  17. Mark R Spaller · 1 shared grant, 2021 · strength 0.44
  18. Yanxi Lu · 2 shared papers, 2024–2025 · strength 0.36
  19. Gloria M. Petersen · 3 shared papers, 1 shared grant, 2012–2018 · strength 0.29
  20. Thomas C. Smyrk · 3 shared papers, 1 shared grant, 2012–2018 · strength 0.28
  21. Hai Yang · 2 shared papers, 2022–2024 · strength 0.27
  22. Nathalie Britzen‐Laurent · 2 shared papers, 2022–2024 · strength 0.27
  23. Shuman Zhang · 2 shared papers, 2022–2024 · strength 0.27
  24. Naureen Javeed · 5 shared papers, 2012–2019 · strength 0.27
  25. Daniel D. Billadeau · 1 shared paper, 1 shared grant, 2018–2019 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.